X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Pfizer Joins J&J, Moderna On Price, Tech In Shareholder Vote

Content Team by Content Team
28th February 2022
in News
Abzena Invests $60M Into cGMP Manufacturing Capacity

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

It’s no secret that pharmaceutical companies have been criticised for their unequal access to COVID-19 vaccines. Oxfam has won several battles to obtain pricing and intellectual property information from Johnson & Johnson, Pfizer, and Moderna.

Shareholders of J&J will have an opportunity to vote on an Oxfam proposal to compel the company to release its COVID-19 vaccine pricing strategy. Oxfam had previously asked J&J to reveal the data because the drug company had received significant US government funding to develop the shot. According to Oxfam, 32% of J&J shareholders ended up voting for a similar resolution last year.

On the other hand, Moderna and Pfizer shareholders will decide whether to investigate the possibility of sharing vaccine technology to boost global production. Many of the world’s mRNA shots went to developed countries, leaving low- and middle-income countries waiting for generosity. Ever since Oxfam submitted the shareholder resolutions late last year, the multinationals asked the SEC to eliminate them from their annual meeting materials.

As per Oxfam, all three resolutions (Pfizer, J&J, and Moderna) withstood SEC pleas and are progressing forward. Moderna’s request was denied because it goes beyond regular business matters and seeks to micro-manage the business. The SEC disagreed with J&J’s public disclosures that they substantially implemented the proposal. Various global groups have criticised the vaccine heavyweights since the COVID-19 immunisation drive began last year. Vaccine patents were questioned last March as it became clear that developing countries would face a serious supply shortage. In May 2021, the Biden administration endorsed a WTO proposal to revoke intellectual property protections for COVID shots, allowing companies worldwide to produce their own doses.

The move enraged the industry, which argues that established vaccine players are best placed to quickly ramp up production. Companies claim that dissolving patent rights will lead to a global raw material war, reducing output.

In the meantime, COVID vaccine sales have soared, particularly at Pfizer and Moderna. 2021 COVID-19 vaccine sales were $36.8 billion for Pfizer and $17.7 billion for Moderna.

Previous Post

World's first WHO Maturity Level drug regulator is Singapore

Next Post

Study derives Rogue antibodies linked to COVID-19 clotting

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Study derives Rogue antibodies linked to COVID-19 clotting

Study derives Rogue antibodies linked to COVID-19 clotting

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In